Truist Financial Corp Aerie Pharmaceuticals Inc Transaction History

Truist Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 22, 2022	BUY	$4.95 - $9.16 $175,888 - $325,482	35,533 New	35,533 $266,000
Q4 2021 Feb 14, 2022	SELL	$7.02 - $13.33 $204,513 - $388,342	-29,133 Closed	0 $0
Q3 2021 Nov 05, 2021	BUY	$11.32 - $16.63 $8,920 - $13,104	788 Added 2.78%	29,133 $332,000
Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $21,769 - $27,240	1,436 Added 5.34%	28,345 $454,000
Q1 2021 May 17, 2021	BUY	$13.12 - $20.9 $179,665 - $286,204	13,694 Added 103.62%	26,909 $481,000
Q4 2020 Nov 19, 2021	SELL	$9.12 - $14.49 $24,240 - $38,514	-2,658 Reduced 16.75%	13,215 $178,000
Q4 2020 Feb 18, 2021	BUY	$9.12 - $14.49 $44,706 - $71,029	4,902 Added 44.68%	15,873 $214,000
Q3 2020 Nov 13, 2020	BUY	$10.46 - $14.46 $114,756 - $158,640	10,971 New	10,971 $129,000
Q1 2020 May 15, 2020	SELL	$11.84 - $25.52 $136,669 - $294,577	-11,543 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$17.72 - $25.1 $204,541 - $289,729	11,543 New	11,543 $279,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.